Clinical trial

PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

NCT04819243

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-08-25

PhasePHASE2

Study timeline

Study start (actual)2021-08-25Date precision: day

Registry last updated2025-01-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Premenopausal HR+/HER2- Metastatic Breast Cancerunresolved

Interventions

Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, AtezolizumabDRUG

Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,DRUG

Sponsors & collaborators

Samsung Medical Centerlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04819243 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.